Proceedings of the American Thoracic Society
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Proceedings of the American Thoracic Society 6:419-430 (2009)
© 2009 The American Thoracic Society
doi: 10.1513/pats.200903-011AW
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in Proceedings of the American Thoracic Society
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Massey, K. A.
Right arrow Articles by Schnitzer, J. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Massey, K. A.
Right arrow Articles by Schnitzer, J. E.

Targeting and Imaging Signature Caveolar Molecules in Lungs

Kerri A. Massey1,2 and Jan E. Schnitzer1,2

1 Proteogenomics Research Institute for Systems Medicine, San Diego, California; and 2 Sidney Kimmel Cancer Center, San Diego, California

Correspondence and requests for reprints should be addressed to Jan E. Schnitzer, M.D., Proteogenomics Research Institute for Systems Medicine, 11107 Roselle St., San Diego, CA 92121. E-mail: jschnitzer{at}prism-sd.org

ABSTRACT

A major goal of molecular medicine is to target imaging agents or therapeutic compounds to a single organ. Targeting imaging agents to a single organ could facilitate the high-resolution, in vivo imaging of molecular events. In addition, genetic and acquired diseases primary to a single organ, such as cystic fibrosis, tuberculosis, lung cancer, pulmonary fibrosis, pulmonary hypertension, and acute respiratory distress syndrome, could be specifically targeted in the lung. By targeting and concentrating imaging agents or therapeutics to the lungs, deleterious side effects can be avoided with greater efficacy at much lower dosages. Pathologic changes can be identified earlier and followed over time. In addition, therapeutics that have been abandoned due to toxicities may find renewed utility when coupled with specific targeting agents such as antibodies. To achieve these goals, distinct molecular signatures must be found for each organ or disease-state.

Key Words: vascular endothelial cells • whole-body imaging • proteomics • intravital microscopy • transcytosis


Related articles in Proceedings of the American Thoracic Society:

Chair's Summary
Vladimir R. Muzykantov
Proceedings of the American Thoracic Society 2009 6: 398-402. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Thoracic Society. 		 
Registrer for the conference